Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 51 | 2025 | 499 | 11.470 |
Why?
|
Oropharyngeal Neoplasms | 23 | 2025 | 163 | 8.850 |
Why?
|
Carcinoma, Squamous Cell | 39 | 2024 | 662 | 8.430 |
Why?
|
Papillomavirus Infections | 14 | 2025 | 288 | 3.630 |
Why?
|
Laryngeal Neoplasms | 8 | 2023 | 80 | 3.010 |
Why?
|
Metformin | 8 | 2023 | 150 | 2.530 |
Why?
|
Veterans | 14 | 2023 | 1754 | 2.460 |
Why?
|
Antineoplastic Agents | 13 | 2024 | 1668 | 2.190 |
Why?
|
Thyroid Neoplasms | 10 | 2021 | 199 | 2.170 |
Why?
|
Osteoradionecrosis | 4 | 2025 | 13 | 2.070 |
Why?
|
Thyroid Carcinoma, Anaplastic | 7 | 2021 | 16 | 1.720 |
Why?
|
Fibroblasts | 13 | 2011 | 891 | 1.700 |
Why?
|
Laryngectomy | 7 | 2023 | 25 | 1.660 |
Why?
|
Dinoprostone | 11 | 2022 | 76 | 1.490 |
Why?
|
Mouth | 3 | 2021 | 61 | 1.430 |
Why?
|
Mouth Neoplasms | 4 | 2022 | 84 | 1.420 |
Why?
|
Tumor Suppressor Protein p53 | 11 | 2024 | 724 | 1.410 |
Why?
|
Wound Healing | 16 | 2019 | 459 | 1.330 |
Why?
|
Biomarkers, Tumor | 12 | 2023 | 1473 | 1.330 |
Why?
|
Deglutition Disorders | 3 | 2019 | 133 | 1.240 |
Why?
|
Lactic Acid | 4 | 2018 | 153 | 1.220 |
Why?
|
Papillomaviridae | 7 | 2022 | 138 | 1.150 |
Why?
|
Cell Line, Tumor | 23 | 2025 | 3342 | 1.130 |
Why?
|
Hypoglycemic Agents | 5 | 2021 | 444 | 1.130 |
Why?
|
Oxidative Stress | 3 | 2025 | 807 | 1.080 |
Why?
|
Cisplatin | 7 | 2024 | 237 | 1.020 |
Why?
|
Humans | 114 | 2025 | 124907 | 0.990 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2023 | 1135 | 0.980 |
Why?
|
Glottis | 7 | 2019 | 31 | 0.970 |
Why?
|
Neoplasm Staging | 7 | 2020 | 1228 | 0.960 |
Why?
|
Smoke | 1 | 2025 | 61 | 0.930 |
Why?
|
Chemoradiotherapy | 6 | 2018 | 104 | 0.920 |
Why?
|
Risk Assessment | 7 | 2025 | 3439 | 0.890 |
Why?
|
Immunity | 1 | 2025 | 189 | 0.890 |
Why?
|
Tumor Microenvironment | 8 | 2025 | 550 | 0.880 |
Why?
|
Cell Movement | 9 | 2014 | 834 | 0.870 |
Why?
|
Retrospective Studies | 36 | 2025 | 16309 | 0.870 |
Why?
|
Pyruvic Acid | 5 | 2018 | 37 | 0.850 |
Why?
|
NF-E2-Related Factor 2 | 5 | 2025 | 113 | 0.840 |
Why?
|
Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.840 |
Why?
|
Free Tissue Flaps | 6 | 2024 | 51 | 0.820 |
Why?
|
Disease-Free Survival | 11 | 2021 | 868 | 0.800 |
Why?
|
Prognosis | 16 | 2023 | 4616 | 0.780 |
Why?
|
Gastrostomy | 2 | 2019 | 85 | 0.780 |
Why?
|
Carcinoma | 6 | 2023 | 285 | 0.750 |
Why?
|
Lung Neoplasms | 2 | 2022 | 1608 | 0.740 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 27 | 0.730 |
Why?
|
Middle Aged | 39 | 2025 | 26755 | 0.720 |
Why?
|
CD8 Antigens | 2 | 2020 | 41 | 0.710 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 721 | 0.700 |
Why?
|
Neoplasms | 7 | 2023 | 2788 | 0.700 |
Why?
|
Veterans Health | 1 | 2021 | 174 | 0.660 |
Why?
|
Aged | 32 | 2025 | 19712 | 0.660 |
Why?
|
Oxidative Phosphorylation | 1 | 2020 | 108 | 0.660 |
Why?
|
Salvage Therapy | 3 | 2023 | 194 | 0.660 |
Why?
|
Mice, Nude | 10 | 2023 | 711 | 0.630 |
Why?
|
Laryngostenosis | 5 | 2014 | 37 | 0.610 |
Why?
|
Larynx, Artificial | 1 | 2018 | 4 | 0.610 |
Why?
|
Voice Quality | 1 | 2018 | 19 | 0.590 |
Why?
|
Male | 50 | 2025 | 61356 | 0.580 |
Why?
|
Radiation Tolerance | 3 | 2015 | 50 | 0.580 |
Why?
|
Combined Modality Therapy | 9 | 2023 | 1249 | 0.580 |
Why?
|
Deoxyglucose | 3 | 2012 | 34 | 0.580 |
Why?
|
Reactive Oxygen Species | 5 | 2017 | 492 | 0.580 |
Why?
|
Smoking | 3 | 2020 | 1044 | 0.570 |
Why?
|
Carbon Isotopes | 3 | 2015 | 277 | 0.570 |
Why?
|
Carbon | 1 | 2018 | 91 | 0.570 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2025 | 1900 | 0.570 |
Why?
|
Mandible | 3 | 2023 | 79 | 0.560 |
Why?
|
Lymph Nodes | 3 | 2018 | 380 | 0.560 |
Why?
|
Alphapapillomavirus | 3 | 2022 | 30 | 0.560 |
Why?
|
Survival Analysis | 7 | 2020 | 1499 | 0.560 |
Why?
|
Neoplasm, Residual | 3 | 2018 | 121 | 0.560 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2024 | 143 | 0.540 |
Why?
|
Female | 47 | 2025 | 66625 | 0.540 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2022 | 100 | 0.530 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2016 | 44 | 0.520 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 422 | 0.510 |
Why?
|
Collagen | 7 | 2011 | 317 | 0.500 |
Why?
|
Disease Management | 1 | 2019 | 521 | 0.500 |
Why?
|
Mutation | 5 | 2018 | 5815 | 0.490 |
Why?
|
Vocal Cords | 5 | 2020 | 65 | 0.490 |
Why?
|
Animals | 32 | 2025 | 34209 | 0.460 |
Why?
|
Mice | 18 | 2025 | 17751 | 0.440 |
Why?
|
Time-to-Treatment | 4 | 2024 | 187 | 0.440 |
Why?
|
Lymphatic Metastasis | 5 | 2024 | 410 | 0.440 |
Why?
|
Glycolysis | 5 | 2018 | 149 | 0.440 |
Why?
|
Interleukin-1beta | 4 | 2012 | 161 | 0.430 |
Why?
|
Follow-Up Studies | 10 | 2021 | 5158 | 0.430 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2020 | 618 | 0.420 |
Why?
|
Neoplasm Invasiveness | 5 | 2021 | 612 | 0.410 |
Why?
|
Glucose | 2 | 2023 | 885 | 0.410 |
Why?
|
Quality of Life | 3 | 2022 | 1948 | 0.410 |
Why?
|
Magnetic Resonance Imaging | 6 | 2024 | 3594 | 0.400 |
Why?
|
Rabbits | 10 | 2012 | 713 | 0.390 |
Why?
|
Survival Rate | 9 | 2021 | 2038 | 0.380 |
Why?
|
Mutant Proteins | 1 | 2011 | 112 | 0.360 |
Why?
|
Salivary Gland Neoplasms | 2 | 2023 | 55 | 0.360 |
Why?
|
Mucous Membrane | 4 | 2012 | 88 | 0.330 |
Why?
|
Cohort Studies | 8 | 2022 | 4789 | 0.330 |
Why?
|
Glutamine | 1 | 2011 | 215 | 0.330 |
Why?
|
Precision Medicine | 2 | 2023 | 317 | 0.320 |
Why?
|
Mitochondria | 4 | 2020 | 692 | 0.310 |
Why?
|
Treatment Outcome | 14 | 2023 | 12355 | 0.310 |
Why?
|
Diabetes Mellitus | 2 | 2014 | 872 | 0.300 |
Why?
|
Risk | 2 | 2021 | 758 | 0.300 |
Why?
|
Adult | 23 | 2025 | 29499 | 0.300 |
Why?
|
Hematoxylin | 2 | 2025 | 8 | 0.300 |
Why?
|
Eosine Yellowish-(YS) | 2 | 2025 | 9 | 0.300 |
Why?
|
Prospective Studies | 6 | 2025 | 6143 | 0.290 |
Why?
|
Trachea | 1 | 2009 | 201 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 4 | 2015 | 1030 | 0.280 |
Why?
|
Multivariate Analysis | 4 | 2016 | 1425 | 0.280 |
Why?
|
Proportional Hazards Models | 6 | 2018 | 1352 | 0.270 |
Why?
|
Keloid | 1 | 2007 | 10 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1237 | 0.270 |
Why?
|
United States | 9 | 2024 | 10881 | 0.270 |
Why?
|
Radiation, Ionizing | 3 | 2015 | 41 | 0.270 |
Why?
|
Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 28 | 0.260 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2021 | 888 | 0.260 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 112 | 0.260 |
Why?
|
Tongue Neoplasms | 2 | 2019 | 19 | 0.250 |
Why?
|
Paraffin Embedding | 1 | 2025 | 33 | 0.240 |
Why?
|
Cell Communication | 2 | 2008 | 167 | 0.240 |
Why?
|
Formaldehyde | 1 | 2025 | 35 | 0.240 |
Why?
|
Tissue Fixation | 1 | 2025 | 38 | 0.240 |
Why?
|
Glossectomy | 2 | 2021 | 7 | 0.230 |
Why?
|
Disease Models, Animal | 8 | 2021 | 4360 | 0.230 |
Why?
|
Staining and Labeling | 1 | 2025 | 187 | 0.230 |
Why?
|
Lip Neoplasms | 1 | 2024 | 4 | 0.230 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2024 | 37 | 0.220 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2024 | 55 | 0.220 |
Why?
|
Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.220 |
Why?
|
Patient Navigation | 1 | 2023 | 25 | 0.220 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2015 | 290 | 0.210 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2021 | 61 | 0.210 |
Why?
|
Cell Culture Techniques | 4 | 2011 | 286 | 0.210 |
Why?
|
Fetus | 5 | 2009 | 585 | 0.210 |
Why?
|
Glutathione Peroxidase | 1 | 2022 | 31 | 0.200 |
Why?
|
Head | 1 | 2023 | 103 | 0.200 |
Why?
|
Deglutition | 2 | 2019 | 49 | 0.200 |
Why?
|
Skin | 2 | 2019 | 512 | 0.200 |
Why?
|
Larynx | 1 | 2023 | 70 | 0.200 |
Why?
|
Hospitals, Veterans | 2 | 2015 | 359 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 2 | 2025 | 2092 | 0.200 |
Why?
|
Minority Groups | 2 | 2023 | 251 | 0.190 |
Why?
|
Papillomavirus Vaccines | 1 | 2023 | 94 | 0.190 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2021 | 582 | 0.190 |
Why?
|
Artificial Intelligence | 1 | 2025 | 246 | 0.190 |
Why?
|
Spouses | 2 | 2019 | 66 | 0.190 |
Why?
|
Organ Transplantation | 1 | 2023 | 165 | 0.190 |
Why?
|
Neoplasm Proteins | 2 | 2019 | 670 | 0.180 |
Why?
|
Extracellular Matrix | 4 | 2011 | 234 | 0.180 |
Why?
|
High-Throughput Screening Assays | 1 | 2021 | 96 | 0.180 |
Why?
|
Leukoplakia | 1 | 2020 | 3 | 0.180 |
Why?
|
Laryngeal Diseases | 1 | 2020 | 32 | 0.180 |
Why?
|
Mandibular Diseases | 1 | 2020 | 9 | 0.180 |
Why?
|
Pharyngeal Diseases | 1 | 2020 | 19 | 0.170 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 354 | 0.170 |
Why?
|
Genes, p53 | 2 | 2011 | 212 | 0.170 |
Why?
|
Cutaneous Fistula | 1 | 2020 | 23 | 0.170 |
Why?
|
Databases, Genetic | 2 | 2020 | 473 | 0.170 |
Why?
|
Electron Transport Chain Complex Proteins | 1 | 2020 | 23 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 237 | 0.170 |
Why?
|
Feasibility Studies | 5 | 2021 | 762 | 0.170 |
Why?
|
Vascularized Composite Allotransplantation | 1 | 2019 | 2 | 0.170 |
Why?
|
Radiodermatitis | 1 | 2019 | 7 | 0.170 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2020 | 70 | 0.160 |
Why?
|
Signal Transduction | 6 | 2023 | 4543 | 0.160 |
Why?
|
HIV Infections | 2 | 2022 | 1897 | 0.160 |
Why?
|
Thyroidectomy | 2 | 2017 | 102 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2021 | 170 | 0.160 |
Why?
|
Interleukin-12 | 1 | 2020 | 114 | 0.160 |
Why?
|
Antibodies, Bispecific | 1 | 2020 | 34 | 0.160 |
Why?
|
HIV | 1 | 2020 | 180 | 0.160 |
Why?
|
Length of Stay | 2 | 2024 | 1311 | 0.160 |
Why?
|
Radiotherapy Dosage | 2 | 2016 | 187 | 0.160 |
Why?
|
Administration, Topical | 1 | 2019 | 141 | 0.160 |
Why?
|
Cicatrix | 3 | 2012 | 123 | 0.160 |
Why?
|
Esomeprazole | 1 | 2019 | 31 | 0.160 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 356 | 0.160 |
Why?
|
Oncolytic Viruses | 1 | 2020 | 72 | 0.160 |
Why?
|
Cyclooxygenase 2 | 2 | 2010 | 159 | 0.160 |
Why?
|
Fibrosis | 2 | 2019 | 435 | 0.160 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 40 | 0.160 |
Why?
|
Aged, 80 and over | 5 | 2018 | 6528 | 0.160 |
Why?
|
Sexual Partners | 1 | 2019 | 87 | 0.160 |
Why?
|
Family Conflict | 1 | 2018 | 18 | 0.160 |
Why?
|
Oncolytic Virotherapy | 1 | 2020 | 84 | 0.160 |
Why?
|
Dermis | 3 | 2007 | 24 | 0.160 |
Why?
|
Databases, Nucleic Acid | 1 | 2019 | 70 | 0.160 |
Why?
|
DNA, Mitochondrial | 1 | 2020 | 211 | 0.160 |
Why?
|
Radiation Injuries | 2 | 2020 | 143 | 0.150 |
Why?
|
Morbidity | 1 | 2019 | 246 | 0.150 |
Why?
|
Respiratory Mucosa | 2 | 2010 | 91 | 0.150 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 824 | 0.150 |
Why?
|
Pentose Phosphate Pathway | 1 | 2018 | 43 | 0.150 |
Why?
|
Incidence | 3 | 2022 | 3146 | 0.150 |
Why?
|
Citric Acid Cycle | 1 | 2018 | 47 | 0.150 |
Why?
|
Time Factors | 7 | 2025 | 6313 | 0.150 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2016 | 65 | 0.140 |
Why?
|
Radiopharmaceuticals | 2 | 2015 | 161 | 0.140 |
Why?
|
Comorbidity | 1 | 2022 | 1533 | 0.140 |
Why?
|
Cell Proliferation | 4 | 2014 | 2307 | 0.140 |
Why?
|
Radiotherapy | 3 | 2019 | 136 | 0.140 |
Why?
|
Platinum Compounds | 1 | 2017 | 6 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 530 | 0.140 |
Why?
|
Self-Management | 1 | 2018 | 98 | 0.140 |
Why?
|
Carcinogenesis | 1 | 2020 | 333 | 0.140 |
Why?
|
Adenoviridae | 1 | 2020 | 605 | 0.140 |
Why?
|
DNA Damage | 2 | 2022 | 516 | 0.140 |
Why?
|
Interleukin-1 | 2 | 2009 | 142 | 0.140 |
Why?
|
Contrast Media | 1 | 2020 | 471 | 0.130 |
Why?
|
Tumor Cells, Cultured | 3 | 2014 | 1068 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 356 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2023 | 806 | 0.130 |
Why?
|
Pharyngeal Muscles | 1 | 2016 | 11 | 0.130 |
Why?
|
Carbon Radioisotopes | 1 | 2015 | 71 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2016 | 57 | 0.130 |
Why?
|
Adenocarcinoma | 2 | 2013 | 998 | 0.120 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 671 | 0.120 |
Why?
|
Metabolism | 1 | 2015 | 42 | 0.120 |
Why?
|
Receptors, Estrogen | 1 | 2019 | 796 | 0.120 |
Why?
|
Risk Factors | 5 | 2025 | 10282 | 0.120 |
Why?
|
Diet | 2 | 2019 | 1138 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 82 | 0.120 |
Why?
|
Carcinoma, Papillary | 1 | 2015 | 77 | 0.120 |
Why?
|
Carcinogens | 1 | 2015 | 153 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 943 | 0.120 |
Why?
|
Tracheal Stenosis | 1 | 2014 | 31 | 0.120 |
Why?
|
Blotting, Western | 4 | 2011 | 1110 | 0.110 |
Why?
|
Laser Therapy | 2 | 2007 | 250 | 0.110 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 1268 | 0.110 |
Why?
|
Fluoresceins | 1 | 2014 | 35 | 0.110 |
Why?
|
Electron Spin Resonance Spectroscopy | 1 | 2013 | 22 | 0.110 |
Why?
|
Texas | 4 | 2020 | 3592 | 0.110 |
Why?
|
Gels | 3 | 2009 | 68 | 0.110 |
Why?
|
Inflammation | 2 | 2019 | 1428 | 0.110 |
Why?
|
Heterografts | 1 | 2014 | 178 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 826 | 0.110 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2013 | 52 | 0.110 |
Why?
|
Metabolomics | 2 | 2021 | 419 | 0.110 |
Why?
|
Cell Death | 1 | 2014 | 239 | 0.100 |
Why?
|
Radiographic Image Enhancement | 1 | 2013 | 41 | 0.100 |
Why?
|
Alcoholism | 1 | 2015 | 231 | 0.100 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 443 | 0.100 |
Why?
|
Neck Dissection | 1 | 2012 | 18 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2012 | 30 | 0.100 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2014 | 171 | 0.100 |
Why?
|
Cells, Cultured | 5 | 2010 | 3061 | 0.100 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2012 | 61 | 0.100 |
Why?
|
Transplantation, Heterologous | 3 | 2014 | 255 | 0.100 |
Why?
|
RNA, Messenger | 3 | 2010 | 2826 | 0.100 |
Why?
|
Tonsillectomy | 1 | 2013 | 97 | 0.100 |
Why?
|
Cost of Illness | 1 | 2013 | 248 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 79 | 0.090 |
Why?
|
Cesium Radioisotopes | 1 | 2011 | 4 | 0.090 |
Why?
|
Flow Cytometry | 1 | 2014 | 804 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 871 | 0.090 |
Why?
|
Glucose Transport Proteins, Facilitative | 1 | 2011 | 14 | 0.090 |
Why?
|
Oncogene Protein v-akt | 1 | 2011 | 30 | 0.090 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2011 | 8 | 0.090 |
Why?
|
Diabetes Complications | 1 | 2012 | 202 | 0.090 |
Why?
|
Receptors, Prostaglandin | 2 | 2010 | 22 | 0.090 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2011 | 129 | 0.090 |
Why?
|
Poverty | 1 | 2013 | 418 | 0.090 |
Why?
|
Oxygen Consumption | 1 | 2011 | 309 | 0.090 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2013 | 208 | 0.090 |
Why?
|
Chromatography, Liquid | 1 | 2011 | 195 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2011 | 284 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1291 | 0.080 |
Why?
|
Mitochondrial Proteins | 1 | 2011 | 237 | 0.080 |
Why?
|
Phenotype | 2 | 2011 | 4260 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2011 | 331 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 2 | 2023 | 467 | 0.080 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 3448 | 0.080 |
Why?
|
Granulation Tissue | 2 | 2005 | 12 | 0.080 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2009 | 64 | 0.080 |
Why?
|
Cyclic AMP | 2 | 2007 | 250 | 0.080 |
Why?
|
Carbon Dioxide | 2 | 2007 | 274 | 0.080 |
Why?
|
Energy Metabolism | 1 | 2014 | 778 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 339 | 0.080 |
Why?
|
Phosphoproteins | 1 | 2011 | 405 | 0.080 |
Why?
|
Immunohistochemistry | 3 | 2025 | 1691 | 0.080 |
Why?
|
Databases, Factual | 3 | 2020 | 1175 | 0.080 |
Why?
|
Lasers | 1 | 2009 | 114 | 0.080 |
Why?
|
Connexin 43 | 1 | 2008 | 30 | 0.080 |
Why?
|
Focal Adhesions | 1 | 2008 | 13 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2011 | 385 | 0.080 |
Why?
|
Gap Junctions | 1 | 2008 | 38 | 0.080 |
Why?
|
Lasers, Gas | 1 | 2008 | 7 | 0.080 |
Why?
|
Cell Cycle | 1 | 2011 | 615 | 0.070 |
Why?
|
Pilot Projects | 2 | 2018 | 1402 | 0.070 |
Why?
|
Tissue Distribution | 2 | 2022 | 388 | 0.070 |
Why?
|
Esophageal Neoplasms | 1 | 2012 | 361 | 0.070 |
Why?
|
Young Adult | 6 | 2020 | 8999 | 0.070 |
Why?
|
Constriction, Pathologic | 2 | 2005 | 241 | 0.070 |
Why?
|
Proteomics | 1 | 2011 | 500 | 0.070 |
Why?
|
Receptor, ErbB-2 | 2 | 2021 | 514 | 0.070 |
Why?
|
Cell Adhesion | 1 | 2007 | 320 | 0.070 |
Why?
|
Cell Survival | 2 | 2014 | 807 | 0.070 |
Why?
|
Up-Regulation | 1 | 2009 | 867 | 0.070 |
Why?
|
Algorithms | 3 | 2021 | 1618 | 0.060 |
Why?
|
RNA, Small Interfering | 2 | 2021 | 670 | 0.060 |
Why?
|
Voice Disorders | 1 | 2005 | 18 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2019 | 451 | 0.060 |
Why?
|
Mouth Mucosa | 1 | 2005 | 52 | 0.060 |
Why?
|
Active Transport, Cell Nucleus | 2 | 2019 | 117 | 0.060 |
Why?
|
Genomics | 1 | 2013 | 1494 | 0.060 |
Why?
|
Splenectomy | 1 | 2005 | 64 | 0.060 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2025 | 35 | 0.060 |
Why?
|
Statistics, Nonparametric | 2 | 2020 | 429 | 0.060 |
Why?
|
Disease Progression | 1 | 2011 | 2052 | 0.060 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2005 | 53 | 0.060 |
Why?
|
Aging | 1 | 2011 | 1189 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2013 | 2886 | 0.060 |
Why?
|
Neoplasm Micrometastasis | 1 | 2024 | 12 | 0.060 |
Why?
|
Anoctamin-1 | 1 | 2024 | 3 | 0.060 |
Why?
|
Observer Variation | 1 | 2025 | 299 | 0.060 |
Why?
|
Skull Base | 1 | 2024 | 54 | 0.060 |
Why?
|
Pneumothorax | 1 | 2005 | 79 | 0.060 |
Why?
|
Immunomodulation | 1 | 2024 | 80 | 0.060 |
Why?
|
Gingiva | 1 | 2023 | 9 | 0.050 |
Why?
|
Treatment Failure | 2 | 2017 | 343 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 1588 | 0.050 |
Why?
|
Immunogenetics | 1 | 2023 | 8 | 0.050 |
Why?
|
Gene Fusion | 1 | 2023 | 55 | 0.050 |
Why?
|
Tensile Strength | 1 | 2003 | 39 | 0.050 |
Why?
|
ROC Curve | 1 | 2025 | 570 | 0.050 |
Why?
|
Clinical Protocols | 1 | 2024 | 236 | 0.050 |
Why?
|
Biomarkers | 2 | 2022 | 3066 | 0.050 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 23 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2011 | 1017 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 4432 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 1274 | 0.050 |
Why?
|
Preoperative Care | 1 | 2025 | 351 | 0.050 |
Why?
|
Models, Biological | 1 | 2007 | 1461 | 0.050 |
Why?
|
Transplantation, Autologous | 1 | 2003 | 298 | 0.050 |
Why?
|
Apoptosis | 2 | 2024 | 1792 | 0.050 |
Why?
|
Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 17 | 0.050 |
Why?
|
Prevalence | 2 | 2023 | 2451 | 0.050 |
Why?
|
Epigenomics | 1 | 2023 | 164 | 0.050 |
Why?
|
Postoperative Care | 1 | 2024 | 297 | 0.050 |
Why?
|
Residence Characteristics | 1 | 2024 | 279 | 0.050 |
Why?
|
Carcinogenicity Tests | 1 | 2021 | 20 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2022 | 3068 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 764 | 0.050 |
Why?
|
Fluorescent Dyes | 1 | 2003 | 262 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2023 | 211 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2023 | 324 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2023 | 356 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2011 | 260 | 0.050 |
Why?
|
Ubiquitin | 1 | 2022 | 142 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2003 | 661 | 0.050 |
Why?
|
Neck | 1 | 2022 | 137 | 0.050 |
Why?
|
Laryngoscopy | 3 | 2008 | 151 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 872 | 0.040 |
Why?
|
Pharyngectomy | 1 | 2020 | 3 | 0.040 |
Why?
|
DNA, Viral | 1 | 2022 | 480 | 0.040 |
Why?
|
Models, Animal | 1 | 2022 | 465 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2020 | 232 | 0.040 |
Why?
|
Blood Vessels | 1 | 2020 | 103 | 0.040 |
Why?
|
Laparoscopy | 1 | 2005 | 488 | 0.040 |
Why?
|
Hyaluronan Receptors | 1 | 2020 | 66 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2021 | 354 | 0.040 |
Why?
|
Composite Tissue Allografts | 1 | 2019 | 2 | 0.040 |
Why?
|
Transcription, Genetic | 2 | 2019 | 1704 | 0.040 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 258 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2007 | 3290 | 0.040 |
Why?
|
SEER Program | 1 | 2020 | 202 | 0.040 |
Why?
|
Heme Oxygenase-1 | 1 | 2019 | 36 | 0.040 |
Why?
|
Swine | 1 | 2003 | 1174 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 285 | 0.040 |
Why?
|
Feeding Methods | 1 | 2019 | 37 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 355 | 0.040 |
Why?
|
Neuroblastoma | 1 | 2024 | 519 | 0.040 |
Why?
|
Phosphorylation | 2 | 2015 | 1626 | 0.040 |
Why?
|
Mice, SCID | 1 | 2020 | 571 | 0.040 |
Why?
|
Models, Anatomic | 1 | 2019 | 99 | 0.040 |
Why?
|
Down-Regulation | 1 | 2021 | 701 | 0.040 |
Why?
|
Telephone | 1 | 2018 | 110 | 0.040 |
Why?
|
Disclosure | 1 | 2019 | 154 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 2043 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 674 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 582 | 0.040 |
Why?
|
Cytochrome c Group | 1 | 2017 | 17 | 0.040 |
Why?
|
Glucose Transporter Type 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
Electron Transport Complex IV | 1 | 2017 | 39 | 0.040 |
Why?
|
Vaccination | 1 | 2023 | 955 | 0.040 |
Why?
|
Tumor Burden | 1 | 2018 | 228 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2019 | 285 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 182 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2022 | 1027 | 0.030 |
Why?
|
Emotions | 1 | 2019 | 364 | 0.030 |
Why?
|
Palate, Soft | 1 | 2016 | 16 | 0.030 |
Why?
|
Cell Line | 2 | 2011 | 2771 | 0.030 |
Why?
|
Immunotherapy | 1 | 2021 | 665 | 0.030 |
Why?
|
Analog-Digital Conversion | 1 | 2015 | 2 | 0.030 |
Why?
|
Propensity Score | 1 | 2016 | 215 | 0.030 |
Why?
|
Signal-To-Noise Ratio | 1 | 2015 | 41 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 151 | 0.030 |
Why?
|
Enzymes | 1 | 2015 | 52 | 0.030 |
Why?
|
Hospitals, Military | 1 | 2015 | 10 | 0.030 |
Why?
|
Sex Distribution | 1 | 2016 | 301 | 0.030 |
Why?
|
Demography | 1 | 2016 | 240 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 164 | 0.030 |
Why?
|
Age Distribution | 1 | 2016 | 415 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2020 | 606 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2015 | 131 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2015 | 48 | 0.030 |
Why?
|
Hydrogen Peroxide | 1 | 2015 | 113 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 313 | 0.030 |
Why?
|
Protein Transport | 1 | 2016 | 369 | 0.030 |
Why?
|
Ribosomal Protein S6 | 1 | 2014 | 13 | 0.030 |
Why?
|
Cognition | 1 | 2019 | 731 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2023 | 2060 | 0.030 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2014 | 17 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2014 | 58 | 0.030 |
Why?
|
Fluorouracil | 1 | 2014 | 128 | 0.030 |
Why?
|
Cellular Senescence | 1 | 2015 | 162 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 375 | 0.030 |
Why?
|
Kinetics | 1 | 2015 | 1325 | 0.030 |
Why?
|
Equipment Design | 1 | 2015 | 600 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2015 | 359 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2013 | 27 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2014 | 626 | 0.030 |
Why?
|
Celecoxib | 1 | 2012 | 32 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 181 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 1699 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 848 | 0.020 |
Why?
|
RNA Interference | 1 | 2014 | 504 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2015 | 344 | 0.020 |
Why?
|
Tracheostomy | 1 | 2014 | 193 | 0.020 |
Why?
|
Esophagectomy | 1 | 2012 | 60 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2019 | 1529 | 0.020 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2011 | 26 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 38 | 0.020 |
Why?
|
Age Factors | 1 | 2018 | 2821 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 315 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2011 | 459 | 0.020 |
Why?
|
Receptors, Glucocorticoid | 1 | 2011 | 122 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2013 | 327 | 0.020 |
Why?
|
Sulfonamides | 1 | 2012 | 264 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2011 | 101 | 0.020 |
Why?
|
Linear Models | 1 | 2012 | 677 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2011 | 150 | 0.020 |
Why?
|
Protein Binding | 1 | 2014 | 1751 | 0.020 |
Why?
|
Pyrazoles | 1 | 2012 | 307 | 0.020 |
Why?
|
Dexamethasone | 1 | 2011 | 275 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 242 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2011 | 400 | 0.020 |
Why?
|
Adolescent | 2 | 2023 | 19341 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2010 | 973 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 1897 | 0.020 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2008 | 20 | 0.020 |
Why?
|
Laryngeal Cartilages | 1 | 2008 | 3 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 459 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2011 | 1231 | 0.020 |
Why?
|
Capillaries | 1 | 2008 | 66 | 0.020 |
Why?
|
NF-kappa B | 1 | 2010 | 457 | 0.020 |
Why?
|
Carboplatin | 1 | 2007 | 77 | 0.020 |
Why?
|
Time | 1 | 2007 | 94 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2008 | 393 | 0.020 |
Why?
|
Paclitaxel | 1 | 2007 | 125 | 0.020 |
Why?
|
Brachytherapy | 1 | 2007 | 75 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2014 | 2907 | 0.020 |
Why?
|
Laryngeal Mucosa | 1 | 2005 | 2 | 0.020 |
Why?
|
Regeneration | 1 | 2008 | 203 | 0.020 |
Why?
|
Spherocytosis, Hereditary | 1 | 2005 | 8 | 0.020 |
Why?
|
Hypertrophy | 1 | 2005 | 102 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2008 | 772 | 0.020 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2005 | 49 | 0.020 |
Why?
|
Pleurodesis | 1 | 2005 | 16 | 0.010 |
Why?
|
Rupture, Spontaneous | 1 | 2005 | 47 | 0.010 |
Why?
|
Blister | 1 | 2005 | 20 | 0.010 |
Why?
|
Rats | 1 | 2011 | 3695 | 0.010 |
Why?
|
Random Allocation | 1 | 2005 | 437 | 0.010 |
Why?
|
Chronic Disease | 1 | 2008 | 1193 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2005 | 512 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 2542 | 0.010 |
Why?
|
Recurrence | 1 | 2005 | 1427 | 0.010 |
Why?
|
Child | 2 | 2005 | 24479 | 0.010 |
Why?
|
Child, Preschool | 1 | 2005 | 14057 | 0.000 |
Why?
|